Results 81 to 90 of about 895 (141)

Cumulative effects of lifelong systemic excess growth hormone on postcranial skeletal morphology in adult mice

Journal of Anatomy, EarlyView.
Our μCT‐based pilot study reveals size and shape disparity in the adult postcranial skeleton of growth‐hormone model (bGH) mice relative to wild‐type mice. bGH mice have larger and more sexually dimorphic bones, with a systemic radiodensity increase in bony sesamoids and associated, but typically uncalcified, soft tissues.
Joseph R. Groenke, Huanhuan Liu, Grace Lach, Abhishek Wajpe, Darlene Berryman, John J. Kopchick, Shouan Zhu, Patrick M. O'Connor   +7 more
wiley   +1 more source

Dupilumab‐Induced Psoriasis in an Adolescent With Severe Atopic Dermatitis: Successful Management With Abrocitinib

Pediatric Dermatology, EarlyView.
ABSTRACT Psoriasiform eruptions have been described in patients treated with dupilumab. This case report describes an adolescent with severe atopic dermatitis who developed a widespread psoriasiform dermatitis 8 months after starting dupilumab. His therapy was switched to abrocitinib resulting in near‐complete resolution of the psoriatic lesions with ...
Grigorios Theodosiou, Åke Svensson
wiley   +1 more source

Significance of Plain Radiography of the Pelvis for the Diagnosis of Ankylosing Spondylitis in Clinical Practice

Bolʹ, Sustavy, Pozvonočnik, 2015
Diagnosis of ankylosing spondylitis is based on characteristic clinical picture of the disease and mandatory identification of sacroiliitis on pelvis X-ray.
А.V. Smirnov, Sh.F. Erdes
doaj   +1 more source

Dual Targeted Therapy as a Treatment Strategy for Refractory Psoriatic Arthritis: Real‐World Effectiveness and Safety From a Prospective Cohort

ACR Open Rheumatology, Volume 8, Issue 8, August 2026.
Objective To describe patient profiles, treatment patterns, clinical outcomes, and safety of intentional dual biologic or targeted synthetic disease‐modifying antirheumatic drug (b/tsDMARD) therapy in psoriatic arthritis (PsA). A subset of patients with PsA continue to experience persistent inflammation despite b/tsDMARD monotherapy.
André Lucas Ribeiro, Zahra Al‐Zahir, Virginia Carrizo Abarza, Khalad Maliyar, Siddhartha Sood, Ahmed Bagit, Muskaan Sachdeva, Sahil Koppikar, Dafna D. Gladman, Jensen Yeung, Vinod Chandran, Lihi Eder   +11 more
wiley   +1 more source

Beyond Glucocorticoids: The Current Landscape and Prospects for Treating Immune Checkpoint Inhibitor‐Induced Autoimmunity

ACR Open Rheumatology, Volume 8, Issue 8, August 2026.
The rapid integration of immune checkpoint inhibitors (ICIs) into standard oncology protocols has birthed a new frontier in clinical rheumatology: immune‐related adverse events (irAEs). By disrupting the programmed cell death‐1 (PD‐1)/PD‐L1 and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) axes to restore antitumor T cell activity, these ...
Xizi Hu, Ji Eun Ryoo, Brian S. Henick, Adam Mor   +3 more
wiley   +1 more source

HLA‐B Associates With Distinct Disease Expression in Juvenile Spondyloarthritis: A Retrospective Cohort Study

ACR Open Rheumatology, Volume 8, Issue 8, August 2026.
Objective This study aimed to investigate for possible association between HLA‐B genotype and disease phenotype in children with juvenile spondyloarthritis (JSpA). Methods This was a cross‐sectional retrospective study of children evaluated at a large tertiary care rheumatology clinic.
Dimitrios V. Bikas, Timothy G. Brandon, Brittney N. Newby, Pamela F. Weiss   +3 more
wiley   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, Volume 78, Issue 8, Page 1674-1686, August 2026.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

Pelvic girdle enthesitis in spondyloarthritis

Journal of the Belgian Society of Radiology, 2013
A 21-year-old woman was admitted to our hospital for a longstanding history of inflammatory type low back pain. There was no significant medical history. Physical examination revealed pressure pain of superior posterior iliac spines.
Langenhove, C Van, Jans, L, Praet, L Van, Carron, P, Elewaut, D, Bosch, F Van Den, Verstraete, K   +6 more
openaire   +5 more sources

Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis

RMD Open
Background Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated 2-year efficacy in non-radiographic axial spondyloarthritis (nr-axSpA) and radiographic axSpA (r-axSpA) phase ...
Sofia Ramiro, Philip J Mease, Denis Poddubnyy, Clementina López-Medina, Tue Wenzel Kragstrup, Dennis McGonagle, Mindy Kim, Vanessa Taieb, Ute Massow   +8 more
doaj   +1 more source

Spondyloarthritis Preceding and Following Inflammatory Bowel Disease Diagnosis and Risk Factors: A Temporal Trends Analysis in a Population‐Based Cohort

Arthritis &Rheumatology, Volume 78, Issue 8, Page 1666-1673, August 2026.
Objective Spondyloarthritides (SpA) and inflammatory bowel disease (IBD) are immune‐mediated diseases with overlap in clinical and immunologic features. However, temporal correlation of SpA and IBD in individual patients and risk factors are not well characterized.
Manasi Agrawal, Christian N. Sørensen, Gry J. Poulsen, Bahar Moghaddam, Percio S. Gulko, Jean‐Frederic Colombel, Tine Jess   +6 more
wiley   +1 more source